We exist to improve the lives
of everyone affected by epilepsy

Reminder that retigabine (Trobalt) will be discontinued in June 2017

16 May 2017

GlaxoSmithKline (GSK) is permanently discontinuing retigabine (Trobalt) from June 2017. It will no longer be available after June.

GSK announced their plan to discontinue Trobalt last year. If you take Trobalt your epilepsy specialist should have already discussed stopping this treatment, and possibly switching to another medicine instead. If you have not already talked to your doctor about stopping Trobalt, it’s important to contact them as soon as possible. This is so you have time to safely stop taking it before stocks run out.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Use our email helpline service -- your question will be sent directly to our trained helpline advisors who will reply to you. If you post a question about your epilepsy as a comment on a page, it may not be replied to so please use the email helpline service.

Want to talk to other people with epilepsy?

Take a look at forum4e our online community for people with epilepsy. Anyone with epilepsy over the age of 16 can join, from anywhere in the world.

Comment about this page?

We welcome feedback on the content of our website. If you have any comments about the page you were reading, then please complete the form below.

All comments are reviewed by a moderator before appearing on the site. Once the comment appears, your name and comment will be seen by other visitors to the site. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant. Comments may also be edited or deleted if they are not relevant to the page on which they are entered.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
This question is for testing whether you are a human visitor and to prevent automated spam submissions.